Rucaparib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
CIPM (Spain), DMC (Denmark) and NICE (England), among others, recommended or restricted rucaparib, while AOTMIT (Poland), AWMSG (Wales) and NYE METODER (Norway) did not recommend it.
Assessment has run over 7.4 years, from 6 Nov 2018 at AWMSG (Wales) to 29 Apr 2026 at DMC (Denmark).
SMC (Scotland) changed its position: restricted on 9 Mar 2020, recommended by 8 Sep 2025.
No assessment is on file from HAS (France), PBAC (Australia) and PHARMAC (New Zealand), each among the eight highest-volume agencies here.
Not every gap is a refusal: for rucaparib, 1 submission was never made — an outcome set by the company rather than the assessor.
The file is active: 12 of 17 records date from 2023 or later.
The programme is broad: 8 distinct indication wordings are recorded for rucaparib by the agencies that label one in English (AWMSG, NICE and SMC).
AWMSG (Wales) was first to assess rucaparib, on 6 Nov 2018; DMC (Denmark) did not open a file until 29 Apr 2026 — a wide spread of 7.4 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 7 years in total.
Restriction is doing real work here: 4 of 12 decisive outcomes narrowed rucaparib to a subgroup rather than accepting or refusing it outright, at NICE (England), SMC (Scotland) and TLV (Sweden).
6 of the 9 agencies here assessed rucaparib more than once, SMC (Scotland) most often at 3 entries — repeat review is the norm for this molecule rather than the exception.
9 of the 18 agencies in this archive hold a record for rucaparib.
The full ledger for rucaparib reads 4 recommended, 4 not recommended, 4 restricted and 2 deferred to NICE, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| NYE METODER (Norway) | 7 Dec 2025 | Monoterapi for vedlikeholdsbehandling av voksne med platinasensitiv residiverende høygradig epitelial eggstokk-, egglede… | not introduced | source |
| SMC (Scotland) | 8 Sep 2025 | As monotherapy for the maintenance treatment of adult patients with advanced (FIGO Stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal… | accepted | source |
| NICE (England) | 16 Apr 2025 | NICE TA1055 | recommended (optimised) | source |
| TLV (Sweden) | 3 Feb 2025 | Rubraca ingår i högkostnadsskyddet med begränsning | restricted subsidy | source |
| AOTMIT (Poland) | 31 Jan 2025 | programu lekowego B.50 „Leczenie chorych na raka jajnika, raka jajowodu lub raka otrzewnej (ICD-10: C56, C57, C48) | not recommended | source |
12 further decisions for rucaparib, across 7 agencies, are not shown here. They include the most recent record on file, 29 Apr 2026 from DMC (Denmark); its outcome is in the subscriber dataset. They link to 12 further source documents.
Related molecules
- atezolizumab — same ATC class L01X — Antineoplastics
- olaparib — same ATC class L01X — Antineoplastics
- durvalumab — same ATC class L01X — Antineoplastics
- aflibercept — same ATC class L01X — Antineoplastics
- osimertinib — same ATC class L01X — Antineoplastics
- venetoclax — same ATC class L01X — Antineoplastics
Coverage: 17 decisions for rucaparib from 9 agencies, 2018 to 2026. Data to 7 Sep 2026. ATC class L01X — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.